HOME >> MEDICINE >> NEWS
Asthmatx completes enrollment in pivotal study of bronchial thermoplasty

San Francisco, CA, May 21, 2007 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.

Leading asthma and bronchoscopy experts are participating in this international, multicenter AIR2 Trial to establish the safety and efficacy of the Alair System. Nearly 300 patients were enrolled in the study during the last 18 months at over 30 world-renowned medical centers including 15 US research hospitals. The AIR2 Trial is the fourth clinical study of the Alair Bronchial Thermoplasty System. To date, over 700 bronchoscopic procedures have been performed on asthma patients.

"We are very pleased to be a participant in this very important AIR2 Trial, the success of which will result in an important advancement in the treatment of severe asthma," states Mario Castro, MD, Associate Professor at the Washington University School of Medicine and Asthma Center, and a Principal Investigator in the AIR2 Trial. "As the lead enrolling center in the United States, we have experienced significant patient interest in bronchial thermoplasty, which we hope may become a new option for patients with difficult-to-treat asthma."

Final results of the first randomized and controlled clinical study of bronchial thermoplasty, the Asthma Intervention Research (AIR) Trial, were also reported today at the annual scientific assembly of the American Thoracic Society (ATS) by Gerard Cox, MB, Professor of Medicine, McMaster University, Canada, and principal investigato
'"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
21-May-2007


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Approval to start US BTT pivotal trial
6. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
7. New data show CAS in clinical practice has comparable MAE rate with pivotal sapphire trial
8. Now is a pivotal point in history to abolish state execution
9. Orqis Medical receives unconditional FDA approval for pivotal trial of percutaneous CHF therapy
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. Penn study finds pro-death proteins required to regulate healthy immune function

Post Your Comments:
(Date:7/21/2014)... kill cancer cells could boost the effectiveness of chemotherapy ... a new study reports. , Scientists at The Institute ... genetically engineered version of the virus used to vaccinate ... alongside isolated limb perfusion chemotherapy given directly to ... an alternative to amputation was more effective in ...
(Date:7/21/2014)... July 22, 2014 On Monday, September 22, ... Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll West ... begins with registration and lunch at 11 a.m. The ... prizes. Price increases to $250 after September 7th. ... $100 per person. The dinner will include a special ...
(Date:7/21/2014)... July 22, 2014 MillionaireCasket.com, a well-known casket ... maple caskets to its website. In addition to ... 26 percent off) for all these brand new items. ... it provides great caskets for its current and ... mahogany caskets, and oak caskets and more. According to the ...
(Date:7/21/2014)... As reported by CBS Local Pittsburgh in the article ... (7/15), thrill-seeking participants raised $100,000 to raise drug abuse ... Philly. 100 people, including some well-known local news reporters, ... Hotel. Some of the participants shared stories of their ... son killed himself after a long battle with addiction. ...
(Date:7/21/2014)... Cannabis Now Magazine recently announced that ... summer. During these festivals, they will strengthen their relationship ... resources to attendees in an effort to continue their ... legitimate and beneficial side of cannabis. , The publication ... the Kush Expo in Anaheim, the Champs Trade Show ...
Breaking Medicine News(10 mins):Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:Cheap Maple Caskets Recently Added To China Casket Manufacturer MillionaireCasket.com’s Product Line 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Cannabis Now Magazine Hits the Marijuana Festival Circuit and Sponsors Two Major Events 2
(Date:7/21/2014)...  Champions Oncology (OTC: CSBR), a company engaged in ... personalize the development and use of oncology drugs, today ... for the fourth quarter and fiscal year ended April ... close. The company will host a conference ... p.m. EDT (1:30 p.m. PDT). To participate in the ...
(Date:7/21/2014)... Decision Resources Group finds that the ... than triple, reaching nearly $12 billion by 2023, ... first disease-modifying therapies (DMTs), a landmark event in ... include the anti-beta-amyloid monoclonal antibodies solanezumab (Eli Lilly) ... inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn sales of $7 billion ...
(Date:7/21/2014)... , July 21, 2014 ... is utilizing the CompuMed, Inc. (OTCPink: CMPD) ... improve donor organ recovery. CompuMed Enterprise OPO ... real-time access to its Board-Certified specialists for ...      (Logo: http://photos.prnewswire.com/prnh/20140721/697628) ...
Breaking Medicine Technology:The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 2The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 3Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 2Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 3
Cached News: